Inhibrx Biosciences INBX
NASDAQ INBX
$104.70 +2.99 (+2.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Inhibrx Biosciences (INBX) EBIT (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) recorded EBIT of -$32.15 million in Q2 2026, compared with -$27.39 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBIT (2023 - 2026) Analysis & Trends

On a TTM basis, Inhibrx Biosciences' EBIT came in at -$124.27 million as of Jun 30, 2026; for FY2025, it came in at -$135.03 million.

  • Across earlier years, EBIT came in at -$331.45 million in FY2024 and -$219.22 million in FY2023.
  • Quarterly EBIT has ranged from -$160.9 million in Q2 2024 to -$27.39 million in Q2 2025 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 7.14 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 6.43 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -584.00 Mn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 4.75 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 3.16 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 3.51 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -10.39 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 4.27 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 1.25 Bn
10 Inhibrx Biosciences 1.50 Bn 1.50 Bn - -32.15 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.15 Mn
Dec 31, 2025 -30.92 Mn
Sep 30, 2025 -33.81 Mn
Jun 30, 2025 -27.39 Mn
Mar 31, 2025 -42.90 Mn
Dec 31, 2024 -49.93 Mn
Sep 30, 2024 -46.80 Mn
Jun 30, 2024 -160.90 Mn
Mar 31, 2024 -73.83 Mn
Dec 31, 2023 -88.29 Mn
Sep 30, 2023 -45.83 Mn
Jun 30, 2023 -41.34 Mn
API Access

Inhibrx Biosciences EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=INBX&period=max&api_key=YOUR_API_KEY